Vertex Pharmaceuticals

VRTX

Market cap $114B

These players each are leaders in their specialty areas and have generated billions of dollars in revenue. This list includes a biotech stock, a pharma player, and a medical device company.

Vertex Pharmaceuticals Incorporated (VRTX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Vertex (VRTX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced business and program updates ahead of upcoming investor meetings in January, including the company's scheduled webcast from the 44th annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026, at 5:15 p.m. ET/2:15 p.m. PT. “2025 was a year of strong commercial execution and rapid R&D progress, setting up the company for continued growth and many important milestones in 2026,” said Reshma Ke.

Alphabet is playing to win in the AI market. Micron is arguably the biggest AI bargain around.

In the most recent trading session, Vertex Pharmaceuticals (VRTX) closed at $463.86, indicating a -1.24% shift from the previous trading day.

Vertex Pharmaceuticals (VRTX) reached $469.68 at the closing of the latest trading day, reflecting a -2.99% change compared to its last close.

Vertex (VRTX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

This selection of stocks offers interesting buys throughout industries -- from tech to healthcare. Many of these players are trading at bargain levels.

Alphabet should continue to benefit from a strong AI tailwind in 2026. Vertex Pharmaceuticals has several growth drivers in the new year.